The effect of raw yellow onion consumption on plasma levels of hormonal/metabolic parameters in patients with primary breast cancer: A randomized controlled clinical trial

The effect of raw yellow onion consumption on plasma levels of hormonal/metabolic parameters in patients with primary breast cancer: A randomized controlled clinical trial trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012103111335N1

Enrollment

Registered

2012-12-30

Start date

2012-11-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention Group: 2 medium row yellow onion (total:130±30gr)/day for 8 weeks. Intervention 2: Control groups: 2 small row yellow onion (total:30gr)/day for 8 weeks.

Treatment - Drugs

Placebo

Intervention Group: 2 medium row yellow onion (total:130±30gr)/day for 8 weeks

Control groups: 2 small row yellow onion (total:30gr)/day for 8 weeks

Eligibility

Sex/Gender

Female

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for participants will be: Histopathological confirmed breast Cancer; 30 – 65 years old; BMI <35 kg/m2; moderately active. The exclusion criteria: Energy intake range out of 700-3500kcal; smoking history in recent 1 years; acute chronic disease like other cancers, cardiovascular disease, renal disease, liver disease, hyperthyroidism and other hormonal disorder; allergy to onion consumption; colitis; gastritis; bleeding disorders; allergy; asthma; low blood pressure; history of other benign neoplasms; pregnancy and lactation. Using drug like glucocorticoids, metformin, cyclosporine, epilepsy-related drugs, contraceptive, HRTs, aspirin, methotrexate, uridine 5-phosphate, and colchicines are also considered as exclusion criteria.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hormonal Indices. Timepoint: Baseline and endpoint of the intervention. Method of measurement: Electrochemiluminescence.;Metabolic indices. Timepoint: Baseline and endpoint of the intervention. Method of measurement: Electrochemiluminescence.;Liver-related functional enzymes. Timepoint: Baseline and endpoint of the intervention. Method of measurement: Electrochemiluminescence.	—

Secondary

Measure	Time frame
Intake levels of energy and nutrients. Timepoint: Baseline, middle (4th week) and endpoint of the intervention. Method of measurement: 24-hour dietary record.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 13, 2026